Cinclus Pharma Holding AB (publ) (STO:CINPHA)
Sweden · Delayed Price · Currency is SEK 17.18
-0.28 (-1.60%)
At close: Aug 1, 2025
Chimerix Revenue
Cinclus Pharma Holding AB had revenue of 4.58M SEK in the twelve months ending March 31, 2025, up 55.15% year-over-year. In the year 2024, Cinclus Pharma Holding AB had annual revenue of 4.58M, down -23.14%.
Revenue
4.58M
Revenue Growth
+55.15%
P/S Ratio
174.57
Revenue / Employee
241.05K
Employees
18
Market Cap
799.52M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.58M | -1.38M | -23.14% |
| Dec 31, 2023 | 5.96M | -4.61M | -43.63% |
| Dec 31, 2022 | 10.57M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Swedish Orphan Biovitrum AB | 26.97B |
| Sectra AB | 3.31B |
| Getinge AB | 35.50B |
| Camurus AB | 2.27B |
| Medicover AB | 25.22B |
| Asker Healthcare Group AB | 15.88B |
| Bonesupport Holding AB | 1.06B |
| AddLife AB | 10.44B |